I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Hospital-acquired pneumonia (HAP) is defined as a low respiratory tract infection, which develops 48 h after hospital admission in a patient without infection at admission.\[[@ref1]\] HAP currently ranks second among nosocomial infections and accounts for 25% of the infections in Intensive Care Units.\[[@ref1][@ref2][@ref3][@ref4]\] HAP has a significant impact on the financial burden of health care, and new cases drive the increasing emergence of pathogens with multi- or pan-antibiotic resistance. Therefore, identifying the infectious etiology in different settings is the key step for mitigating or obviating the severe infection in time. Early identification of specific pathogens could significantly improve the morbidity and mortality of HAP, and lower the cost of treatment as well. So far, the most common method used to implement HAP etiology is still tied to sputum culture. Sputum culture, however, shows significant disadvantages pathogens identification. In addition to sputum culture\'s relatively low sensitivity and the difficulty with which it identifies atypical pathogens,\[[@ref1][@ref5][@ref6]\] the time required to obtain results always leads to empirical antibiotic therapies rather than target therapies for patients with HAP. This, in turn, often increases the risk of antibiotic resistance.

An rapid innovative method for etiology identification of HAP, the quantitative loop-mediated isothermal amplification (qLAMP), has already been used in the diagnosis of virus, fungus, parasite, and tuberculosis infections and is now commercially available.\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\] It is a novel assay that focuses on the genetics of pathogens based on rapid nucleic acid amplification method. Therefore, this technique has two important advantages such as rapid diagnosis and high sensitivity.\[[@ref13][@ref14][@ref15]\] In addition, qLAMP is also a high specific assay, which could detect different bacteria with quantified copies.\[[@ref16]\] Since the excellent timeliness and accuracy of qLAMP for etiological diagnosis to the lower respiratory tract infection has been confirmed by our group,\[[@ref16]\] we initiated a pilot, prospective, and interventional study to investigate the value of qLAMP to guide target antibiotics therapies in a small group of patients with HAP.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study design {#sec2-1}
------------

Patients with suspected HAP from August 2011 to March 2014 at Peking University People\'s Hospital (Beijing, China) were recruited in the study, which were approved by the Ethical Committee of Peking University People\'s Hospital (No. 2011-83). All participants provided written informed consents. These patients were initially diagnosed as suspected cases of HAP occurring more than 48 h after admission and were not incubated at the time of admission, having typical characteristics of pneumonia, which were firmly inferred from chest X-rays and the following criteria:\[[@ref17]\] \[I\] at least one of the following: (1) fever (\> 38.5°C), (2) leukopenia (peripheral white blood cell count \[WBC\] \<4.0 × 10^9^/L) or leukocytosis (WBC \>10.0 × 10^9^/L), and (3) for adults 70 years old or older, mental status changes with no other recognized cause; \[II\] at least two of the following: (1) new-onset of purulent sputum, or change in character of sputum, or increased respiratory secretion, or increased suctioning requirements, (2) new-onset or worsening cough, or dyspnea, or tachycardia, (3) rales or bronchial breath sounds, and (4) worsening gas exchange (PaO~2~/FiO~2~ ≤ 240), increased oxygen requirements, or increased ventilation demand. Patients with noninfectious diseases, viral infection, fungal infection, or tuberculosis were subsequently excluded from the study.

Once patients were enrolled, lower respiratory secretion samples were collected on the 1^st^ day for both routine culture and qLAMP assays, of which the results were reported to the clinicians. Data of each patient were also collected from the medical records, with particular attention to clinical manifestations and treatment strategies before and after the qLAMP results reporting.

To determine the final diagnosis and assess the treatment response for each patient, 2 independent pulmonologists blinded to qLAMP results reviewed all available medical records (including patient history, physical examination, and results of laboratory tests, including blood routine examination, biochemical indicators, plasma electrolytes, blood gas analysis, and chest radiograph) pertaining to the patient from the time of HAP presentation to discharge/death. Cases were reviewed and adjudicated by a third pulmonologist when confronting a disagreement.

Procedures {#sec2-2}
----------

After liquefied in an equal volume of 10% NaOH, DNA specimen of each sample was isolated using the Universal Kit for Bacterial DNA Extraction (Capitalbio Corporation, China). The specimens were then prepared for qLAMP using a set of specific primers for *Streptococcus pneumonia* (SP), *Staphylococcus aureus* (SA), *Escherichia coli* (EC), *Klebsiella pneumonia* (KP), *Pseudomonas aeruginosa* (PA), *Acinetobacter baumannii* (AB), *Stenotrophomonas maltophilia* (SM), *Haemophilus influenzae* (HI), *Legionella pneumophila* (LP), *Mycoplasma pneumonia* (MP), and *Chlamydophila pneumoniae* (CP). qLAMP primer system of each species of pathogen is composed of six primers recognizing eight distinct regions on the target DNA, termed a forward outer primer (F3), a backward internal primer (BIP) (B3), a forward internal primer (FIP), a BIP, and loop primers (LF and LB). Eight-pathogen primer sequences are used same as we did before, including SP, SA, EC, KP, PA, AB, SM, and HI.\[[@ref16]\] Those for atypical pathogens were redesigned as shown in [Table 1](#T1){ref-type="table"}, and both their sensitivity and specificity were ensured by quantified DNA isolated in 27 bacterial species as we did before.\[[@ref16]\]

###### 

Primers for atypical pathogens used in this study

  Target species   Primers   Nucleotide sequence
  ---------------- --------- -------------------------------------------------
  LP               F3        GCAAGACGCTATGAGTGG
                   B3        TGATTACTTTGTATTGCAAACCA
                   FIP       GCCATCAAATCTTTCTGAAACTTGT CTCAATTGGCTTTAACCGAAC
                   BIP       GCGGATGAAAATAAAGTAAAAGGGG CTTGGCAATACAACAACGC
                   LF        TAAGAACGTCTTTCATTTGCT
                   LB        CTGAAAACAAAAACAAGCCAG
  MP               F3        GTTAAACCCGCAAACGCC
                   B3        TGCTCATAGTACACCACGCT
                   FIP       TGCAGCCCCACTCAAACCAA GACCAAACCGGGCAGATC
                   BIP       TCAAAAACAAGGTCCCCGTCGA GGCACGAGTAAAACGGCAA
                   LF        CGCCAAAGGGGTTAAAGGT
                   LB        CAAGACCCCTCCAATCCCT
  CP               F3        AATTATAAGACTGAAGTTGAGCA
                   B3        AGAGAGATATGGCATATCCG
                   FIP       TTCTCTTAGAGGCAACGTAGACTTT GGGAGATGCAGATTTAGATCA
                   BIP       TCAAGTTGGAGATAAAATGGCTGG CGGGAACGATTTTGGAAAC
                   LF        ACCTTGGCGAATGACACCA
                   LB        ACGACACGGAAATAAAGGTGTT

FIP: Forward internal primer; BIP: Backward internal primer; LP: *Legionella pneumophila*; MP: *Mycoplasma pneumonia*; CP: *Chlamydophila pneumonia*.

The reaction was performed at 65°C for 45 min in a 25-μl reaction mixture consisting of 1.6 μmol/L each of FIP and BIP, 0.2 μmol/L each of F3 and B3, 0.4 μmol/L each of LF and LB, 8 U of the Bst DNA polymerase large fragment (New England Biolabs Inc., Beverly, Mass., USA), 0.4 mmol/L dNTP, 0.1 mmol/L dUTP, 0.8 mol/L betaine, 6 mmol/L MgSO~4~, 0.5 mg/ml BSA, 0.6 × EvaGreen (Biotium, Inc., CA, USA), 0.1 U/ml Uracil-DNA Glycosylase (Fermentas Inc., MD, USA), 20 mmol/L Tris-HCl (pH 8.8 at 25°C), 10 mmol/L KCI, 10 mmol/L (NH~4~)~2~ SO~4~, 0.1% Triton X-100, and 2 μl template DNA or PCR grade H~2~ O as negative control, and then heated at 80°C for 5 min to terminate the reaction. All amplifications were performed with an RT-cycler Real-time Fluorescence Quantitative PCR Instrument (Capitalbio Corporation, Beijing, China). The titer was quantified according to the standard curves obtained from prequantified DNA templates as described previously.\[[@ref16]\] Biochip technology was introduced in January 2013 at Peking University People\'s Hospital, and the reaction was performed on a microfluidic device after then.

The qLAMP tests and routine cultures were conducted by two experienced technicians awareness of the sample identities in two separated laboratories of Peking University People\'s Hospital.

Statistical analysis {#sec2-3}
--------------------

We constructed a contingency table and used McNemar test to evaluate the congruence of qLAMP and culture results. The differences between patients with or without treatment strategies adjustment based on qLAMP results were tested with Fisher\'s exact test or t test. Baseline data of these patients were expressed as mean ± standard deviation (SD) for normally distributed values. All analyses were performed with the use of SPSS statistics software, version 19.0 (IBM, USA). A *P* \< 0.05 is considered statistically significant difference.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Quantitative loop-mediated isothermal amplification assaying outcome of specimen from hospital-acquired pneumonia patients {#sec2-4}
--------------------------------------------------------------------------------------------------------------------------

Totally, 76 samples were recruited from 110 eligible samples overall in our study \[[Figure 1](#F1){ref-type="fig"}\]. The 76 samples were collected from 60 patients with HAP. None of the samples were collected from the same onset of HAP. As shown in [Table 2](#T2){ref-type="table"}, there were 70 samples with qLAMP results greater than 10^5^ copies/ml, 23 samples with qLAMP results between 10^3^ and 10^5^ copies/ml, and 16 samples with qLAMP results below 10^3^ copies/ml.

![Study profile. For each eligible patient, we collected lower respiratory secretion samples on the 1^st^ day for routine culture and quantitative loop-mediated isothermal amplification tests and reported the results to the clinicians. We also collected the clinical data and treatment strategies before and after reporting the quantitative loop-mediated isothermal amplification results.](CMJ-129-181-g001){#F1}

###### 

qLAMP results of specimen from patients with hospital-acquired pneumonia

  Pathogens   \>10^5^ copies/ml   10^3^--10^5^ copies/ml   \<10^3^ copies/ml   Negative   Total
  ----------- ------------------- ------------------------ ------------------- ---------- -------
  SP          1                   0                        0                   75         76
  SA          11                  5                        6                   54         76
  EC          1                   0                        1                   74         76
  KP          8                   4                        3                   61         76
  PA          17                  3                        0                   56         76
  AB          20                  5                        1                   50         76
  SM          8                   2                        0                   66         76
  HI          1                   1                        3                   71         76
  LP          1                   3                        0                   72         76
  MP          2                   0                        2                   72         76
  CP          0                   0                        0                   76         76
                                                                                          
  Total       70                  23                       16                  727        836

Data are presented as number, unless otherwise indicated. qLAMP: Quantitative loop-mediated isothermal amplification; LP: *Legionella pneumophila*; MP: *Mycoplasma pneumonia*; CP: *Chlamydophila pneumoniae*; SP: *Streptococcus pneumonia*; SA: *Staphylococcus aureus*; EC: *Escherichia coli*; KP: *Klebsiella pneumonia*; PA: *Pseudomonas aeruginosa*; AB: *Acinetobacter baumannii*; SM: *Stenotrophomonas maltophilia*; HI: *Haemophilus influenza*.

Congruence of quantitative loop-mediated isothermal amplification and culture results {#sec2-5}
-------------------------------------------------------------------------------------

The concordance rates of the two assays for detecting SA, EC, PA, KP, SM, SP, and AB are 90.79%, 98.68%, 89.47%, 93.42%, 93.42%, 100.00%, and 77.63%, respectively \[[Table 3](#T3){ref-type="table"}\]. We also evaluated the difference between qLAMP and culture results by McNemar test, in which no significant difference was found (*P* \> 0.05) \[[Table 3](#T3){ref-type="table"} and Supplementary Tables [1](#T4){ref-type="table"}--[7](#T10){ref-type="table"}\]. The qLAMP results of 4 samples for HI, LP, or MP were positive, while the culture results for these specimens were negative probably because of their low detectable rates in culture. We then studied the clinical data of these 4 samples and found that the qLAMP results were all reliable except 1 MP positive sample due to the lack of specific species identified in the final diagnosis. No CP positive results were reported in the 76 samples either by qLAMP or culture assay.

###### 

Congruence of qLAMP and culture results in patients with hospital-acquired pneumonia

  Pathogens   Concordance rate (%)   *P*
  ----------- ---------------------- -------
  SA          90.79                  0.453
  EC          98.68                  1.000
  PA          89.47                  0.070
  KP          93.42                  0.375
  SM          93.42                  0.063
  SP          100.00                 1.000
  AB          77.63                  0.332

qLAMP: Quantitative loop-mediated isothermal amplification; SP: *Streptococcus pneumonia*; SA: *Staphylococcus aureus*; EC: *Escherichia coli*; KP: *Klebsiella pneumonia*; PA: *Pseudomonas aeruginosa*; AB: *Acinetobacter baumannii*; SM: *Stenotrophomonas maltophilia*.

###### 

qLAMP vs culture results for *Staphylococcus aureus*\*

  Culture    qLAMP        
  ---------- ------- ---- ----
  Positive   6       2    8
  Negative   5       63   68
  Total      11      65   76

\*Data are presented as No. qLAMP: Quantitative loopmediated isothermal amplification

###### 

qLAMP vs culture results for *Escherichia coli*\*

  Culture    qLAMP        
  ---------- ------- ---- ----
  Positive   1       1    2
  Negative   0       74   74
  Total      1       75   76

\*Data are presented as No. qLAMP: quantitative loopmediated isothermal amplification

###### 

qLAMP vs culture results for *Pseudomonas aeruginosa*\*

  Culture    qLAMP        
  ---------- ------- ---- ----
  Positive   10      1    11
  Negative   7       58   65
  Total      17      59   76

\*Data are presented as No. qLAMP: Quantitative loopmediated isothermal amplification

###### 

qLAMP vs culture results for *Klebsiella pneumonia*\*

  Culture    qLAMP        
  ---------- ------- ---- ----
  Positive   4       1    5
  Negative   4       67   71
  Total      8       68   76

\*Data are presented as No. qLAMP: Quantitative loopmediated isothermal amplification

###### 

qLAMP vs culture results for *Stenotrophomonas maltophilia*\*

  Culture    qLAMP        
  ---------- ------- ---- ----
  Positive   3       0    3
  Negative   5       68   73
  Total      8       68   76

\*Data are presented as No. qLAMP: Quantitative loopmediated isothermal amplification

###### 

qLAMP vs culture results for *Streptococcus pneumonia*\*

  Culture    qLAMP        
  ---------- ------- ---- ----
  Positive   1       0    1
  Negative   0       75   75
  Total      1       75   76

\*Data are presented as No. qLAMP: Quantitative loopmediated isothermal amplification

###### 

qLAMP vs culture results for *Acinetobacter baumannii*\*

  Culture    qLAMP        
  ---------- ------- ---- ----
  Positive   14      11   25
  Negative   6       45   51
  Total      20      56   76

\*Data are presented as No. qLAMP: Quantitative loopmediated isothermal amplification

Clinical benefit of quantitative loop-mediated isothermal amplification guided target therapy {#sec2-6}
---------------------------------------------------------------------------------------------

A total of 44 qLAMP-positive samples were identified in the study. Treatment strategies were established or adjusted in 23 of them based on qLAMP results. Eight samples were subsequently excluded from analysis because of discharge or death within 3 days after admission. The final analysis group of 36 patients consisted of 19 with treatment established or adjusted to target antibiotics therapies according to qLAMP results (pathogen target-driven therapy group) and 17 without treatment strategies adjustment whose treatment strategy was inconsistent with qLAMP results (empirical therapy group).

**Demographic and clinical characteristics of the two groups**

Demographic and clinical characteristics of the two groups are shown in [Table 4](#T11){ref-type="table"}. There is no significant difference (*P* \> 0.05) in the characteristics of the patients between the two groups, including gender, age, complications, clinical manifestation (temperature, cough, sputum, and rales), blood routine examination, biochemical indicators, blood gas analysis, blood coagulation index, and chest radiograph infiltration.

###### 

Demographic and clinical characteristics of patients in the two groups

  Characteristics                            Patients with pathogen target-driven therapy (*n* = 19)   Patients with empirical therapy (*n* = 17)   Statistics   *P*
  ------------------------------------------ --------------------------------------------------------- -------------------------------------------- ------------ ------
  Male, *n* (%)                              15 (79)                                                   9 (53)                                       2.73\*       0.16
  Age (years)                                74.26 ± 10.99                                             78.00 ± 8.48                                 --1.13^†^    0.27
  Complications, *n* (%)                                                                                                                                         
   Hypoproteinemia                           15 (79)                                                   12 (71)                                      0.33\*       0.71
   Coronary heart disease                    9 (47)                                                    4 (24)                                       2.21\*       0.18
   Acute cerebrovascular disease             4 (21)                                                    5 (29)                                       0.33\*       0.71
  Clinical manifestation                                                                                                                                         
   Temperature, °C                           37.95 ± 1.06                                              37.68 ± 0.81                                 0.85^†^      0.40
   Cough, *n*                                19                                                        17                                           --           --
   Sputum, *n*                               19                                                        17                                           --           --
   Rales, *n*                                19                                                        17                                           --           --
  Blood routine examination (normal value)                                                                                                                       
   WBC, ×10^9^/L (4.0--10.0)                 11.63 ± 5.26                                              10.45 ± 4.55                                 0.72^†^      0.48
   NE, % (50--70)                            81.48 ± 10.74                                             85.37 ± 9.80                                 --1.13^†^    0.27
   NE, ×10^9^/L (2.0--7.0)                   9.60 ± 5.01                                               9.08 ± 4.50                                  0.33^†^      0.74
   Hb, g/L (110--170)                        103.32 ± 19.83                                            96.84 ± 19.51                                0.99^†^      0.33
   Platelet, ×10^9^/L (100--300)             211.21 ± 104.93                                           197.20 ± 88.14                               0.43^†^      0.67
  Biochemical indicators (normal value)                                                                                                                          
   ALT, U/L (0--40)                          41.11 ± 68.58                                             28.35 ± 17.39                                0.74^†^      0.46
   AST, U/L (0--40)                          36.95 ± 29.20                                             35.06 ± 20.13                                0.22^†^      0.83
   ALB, g/L (35--55)                         31.59 ± 3.57                                              30.38 ± 5.46                                 0.80^†^      0.43
   CRE, µmol/L (20--106)                     76.21 ± 73.42                                             70.00 ± 39.52                                0.31^†^      0.76
   BUN, mmol/L (2.9--8.3)                    10.28 ± 7.80                                              10.28 ± 5.64                                 0.0002^†^    1.00
  Blood gas analysis (normal value)                                                                                                                              
   pH (7.35--7.45)                           7.52 ± 0.05                                               7.51 ± 0.06                                  0.91^†^      0.37
   PaO~2~, mmHg (80.0--100.0)                115.17 ± 43.97                                            97.47 ± 32.29                                1.36^†^      0.18
   PaCO~2~, mmHg (35--45)                    38.79 ± 8.03                                              40.12 ± 9.56                                 --0.45^†^    0.65
   HCO~3~^−^, mmol/L (21.4--27.3)            31.97 ± 6.47                                              31.57 ± 6.37                                 0.19^†^      0.85
   Oxygenation index, mmHg (400--500)        230.02 ± 113.91                                           229.10 ± 96.36                               0.03^†^      0.98
  Blood coagulation index (normal value)                                                                                                                         
   PT, s (9.8--13.1)                         12.81 ± 2.13                                              14.05 ± 5.90                                 --0.82^†^    0.42
   APTT, s (25.4--38.4)                      33.22 ± 6.85                                              32.88 ± 6.32                                 0.15^†^      0.88
  Chest radiograph infiltration, *n* (%)     19 (100)                                                  17 (100)                                     --           --

Data are presented as mean ± SD unless otherwise indicated. \**χ*^2^ value; ^†^*t* value. "--": Data not applicable; SD: Standard deviation; WBC: White blood cell; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; CRE: Creatinine; BUN: Blood urea nitrogen; PT: Prothrombin time; APTT: Activated partial thromboplastin time; NE: Neutrophil count.

**Patients taking an advantage for clinical condition with pathogen target-driven therapy**

There are 16 patients from the pathogen target-driven therapy group with clinical condition improvement 3 days after qLAMP results reported, while there is only 1 from the empirical therapy group. The remission rate is 84.2% in the group with pathogen target-driven therapy, and 5.9% in the group with empirical therapy. The differences in the remission rates between these two groups evaluated by Fisher\'s exact tests are statistically significant (*P* = 2 × 10^−\ 6^).

Daily mean temperature of the group with pathogen target-driven therapy shows a more obvious tendency of improvement than the group with empirical therapy \[[Figure 2](#F2){ref-type="fig"}\]. On the 1^st^ day when samples were collected, the mean temperature of target-driven therapy group and empirical therapy group were 37.95°C and 37.68°C, respectively, while the mean temperature of those two groups changed to 37.42°C and 38.02°C 3 days later. The decrease of daily mean temperature was 0.53°C in the group with pathogen target-driven therapy while the decrease in the group with empirical therapy was −0.34°C. Similarly, decrease of total WBC number in group with pathogen target-driven therapy is more significant than the group with empirical therapy (2.15 × 10^9^/L with pathogen target-driven therapy vs. 0.70 × 10^9^/L with empirical therapy) \[[Figure 3](#F3){ref-type="fig"}\].

![Temperature alteration between two groups. The body temperature of the group with pathogen target-driven therapy decreased while the group with empirical therapy had no significant improvement in body temperature.](CMJ-129-181-g002){#F2}

![White blood cell (WBC) count alteration between two groups. The WBC count of the group with pathogen target-driven therapy decreased while the group with empirical therapy fluctuated in WBC count.](CMJ-129-181-g003){#F3}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This is a pilot study to assess the value of qLAMP in guiding early target antibiotic therapies of HAP, which may have significant effects on the mortality of HAP and reduce the cost. Although bacterial pneumonia is a kind of curable diseases due to the advent of the antibiotics, the mortality of bacterial HAP is still high, which may contribute to the delay of target antibiotics therapies according to the results of sputum culture.

As a new manner of detecting the etiology of different kinds of infections, qLAMP is now commercially available. With the availability of this rapid (results are available within 1--2 h), sensitive, and specific test, early target antibiotic therapy of infection is now possibly feasible. Therefore, we apply qLAMP for the decision-making regarding whether we selected empirical antibiotic therapies or the target antibiotic therapies for HAP patients.

Since we would investigate the value of qLAMP steering therapies, the first important issue was whether qLAMP can etiologically diagnose HAP in time. As qLAMP assay was much more rapid than sputum culture, the most common assay in recent clinical practice, we first focus on the congruency of the results of qLAMP and sputum culture. Fortunately, there was no significance between qLAMP and culture results of HAP patients with infections of SA, EC, PA, KP, SM, SP, and AB. In addition, qLAMP can detect HI, LP, and MP, which were not detectable by culture. Besides, qLAMP was a candidate method which could differentiate the pathogens between colonized and infectious status. After that, we prospectively enrolled 36 patients with HAP with the same baseline data to evaluate the value of qLAMP steering early target therapies. Among these patients, the qLAMP results were all positive based on the cut-off value (\>1.0 × 10^5^ copies/ml) which was established in our former work (data not shown). We randomly adjusted the regimen of these patients with empirical therapies according to the 2005 American Thoracic Society/Infectious Diseases Society of America HAP guideline\[[@ref1]\] or target therapies based on the results of qLAMP. Interestingly, we found that the clinical condition was significantly improved in the group with pathogen target-driven therapy compared to the group with empirical therapies.

There are a few limitations in our studies. Firstly, it was performed with a small sample size, and the stochastic effects were too big to drive a definite conclusion. Secondly, we did not test the infection of fungus and virus of HAP, which may contribute a small number of HAP infections. Thirdly, we did not assess the immunological conditions and nutritional statuses of the patients in these two groups, which may influence the effects of antibiotic therapies. A forth limitation was that the drug sensitivity cannot be tested by qLAMP. Perhaps, we could combine qLAMP and sputum drug sensitivity test to individualize the HAP regimens. However, the definition of conclusion can only be driven after multi-centered, randomized, and large sample sized research. Since qLAMP cannot test the drug sensitivity, the combination of qLAMP and sputum culture is the good choice for guiding early target therapies in HAP patients.

In conclusion, the qLAMP assay is a reliable alternative for steering early target therapies of HAP.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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